|
|
Amicus Therapeutics inc (NASDAQ: FOLD) |
|
Price: $5.6400
$-0.09 
-1.571%
|
| Day's High:
| $5.77
| Week Perf:
| -8.59 %
|
| Day's Low: |
$ 5.62 |
30 Day Perf: |
-12.29 % |
| Volume (M): |
17,425 |
52 Wk High: |
$ 12.65 |
| Volume (M$): |
$ 98,279 |
52 Wk Avg: |
$9.41 |
| Open: |
$5.75 |
52 Wk Low: |
$5.62 |
|
|
| Market Capitalization (Millions $) |
1,735 |
| Shares
Outstanding (Millions) |
308 |
| Employees |
1,246 |
| Revenues (TTM) (Millions $) |
542 |
| Net Income (TTM) (Millions $) |
-29 |
| Cash Flow (TTM) (Millions $) |
-28 |
| Capital Exp. (TTM) (Millions $) |
2 |
Amicus Therapeutics Inc
Amicus Therapeutics is an American biopharmaceutical company founded in 2002, based in Cranbury, New Jersey. The company is focused on developing and commercializing new treatments for rare and orphan diseases, including lysosomal storage disorders (LSDs) of genetic origin.
The company's mission is to unlock the potential of genetic medicine to improve the lives of people affected by rare and devastating diseases. They are dedicated to conducting rigorous research to uncover new therapeutic approaches to these diseases, and to bringing safe and effective treatments to market.
Amicus Therapeutics has a diverse portfolio of small molecule and gene therapy drug candidates that are designed to address various LSDs. They currently have three approved products: Galafold, a small molecule medication for the treatment of Fabry disease, which is a genetic disorder that leads to the accumulation of a type of fat in the body called globotriaosylceramide (Gb3); Migalastat, an oral medication that is used in combination with enzyme replacement therapy (ERT) for patients with Fabry disease; and Jivi, a recombinant factor VIII therapy used for the treatment of hemophilia A.
In addition to their approved products, Amicus Therapeutics also has several promising drug candidates in development, such as AT-GAA, a gene therapy for Pompe disease that is currently in Phase 3 clinical trials.
Amicus Therapeutics has a strong commitment to patient advocacy and engagement, working closely with patient organizations and advocacy groups to ensure that the needs and concerns of patients are taken into account in their research and development efforts.
Overall, Amicus Therapeutics is a leading company in the field of rare and orphan diseases, with a strong focus on developing innovative and effective treatments to improve the lives of patients affected by these devastating conditions.
Company Address: 47 Hulfish Street Princeton 8542 NJ
Company Phone Number: 662-2000 Stock Exchange / Ticker: NASDAQ FOLD
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Amicus Therapeutics Inc
Amicus Therapeutics Inc, a major player in the pharmaceutical preparations industry, recently announced its financial results for the first quarter of 2024. While the company experienced a surge in revenue compared to the previous year, it also reported a net loss. Furthermore, the stock's performance in the market has been relatively volatile. This article will delve into the implications of these financial results and speculate on how they might affect Amicus Therapeutics Inc's future prospects.
Positive Revenue Growth:
One promising aspect of Amicus Therapeutics Inc's financial results is its revenue growth in Q1 2024. The company witnessed an impressive 27.317% increase in revenue, reaching $109.84 million compared to the corresponding period the prior year. This growth significantly outpaced most of its counterparts in the major pharmaceutical preparations sector, which only reported an average revenue improvement of 2.72% during the same period. This indicates that Amicus Therapeutics Inc is performing well in terms of generating revenue.
|
| Amicus Therapeutics Inc
Amicus Therapeutics Inc, a major player in the pharmaceutical preparations industry, recently announced its financial results for the fourth quarter of 2023. Despite reporting a net loss of $-0.11 per share, the company's revenue experienced a significant surge of 31.466%, amounting to $115.82 million. This represents a remarkable 21% increase in total revenue compared to the previous year.
When compared to the preceding quarter, where the company generated $102.56 million in revenue and reported a net loss of $-0.07 per share, these figures demonstrate promising growth for Amicus Therapeutics Inc. Furthermore, the company's net shortfall decreased from $-55.865 million to $-33.843 million in the same fiscal fourth quarter, indicating improved financial performance.
|
| Amicus Therapeutics Inc
Amicus Therapeutics Inc, a major pharmaceutical preparations company, recently reported a significant surge in revenue by 25.54% to $102.56 million for the fiscal time-frame ending September 30, 2023. This growth outpaced many of its industry competitors. However, upon further analysis, it is evident that there are several concerning factors that indicate a bearish outlook for the company.
First and foremost, Amicus Therapeutics Inc's deficit has extended to $-0.07 per share, which is an alarming figure for investors. While the company's revenue has grown, the fact that it is still operating at a deficit raises concerns about its financial stability and ability to generate sustainable profits.
|
| Amicus Therapeutics Inc
Amicus Therapeutics Inc, a pharmaceutical company, has experienced a slight decrease in its shares over the past five trading days. The shares went down by -0.26%, which brings the year-to-date performance to 13.75%. Despite this decrease, it is worth noting that the shares are only 2% short of the 52-week high, indicating a strong performance overall.
Looking at the company's financial performance, it can be observed that for the April to June 30, 2023 fiscal period, there was a significant increase in losses compared to the same period the previous year. The losses swelled to $-0.15 per share, whereas they were $0.00 per share a year before. However, there was an improvement in earnings per share from the prior quarter, increasing from $-0.18 per share.
|
| Amicus Therapeutics Inc
Investing in the stock market can be an exciting and rewarding experience. However, it is crucial to approach investment decisions with caution and careful consideration. This is especially true when it comes to investing in individual companies and stocks that are subject to fluctuations in performance, such as Amicus Therapeutics Inc.
According to recent financial reports released by Amicus Therapeutics Inc, the company's shortfall per share has expanded to $-0.18 from $0.00 year on year. This is a significant change in performance and should be of concern to investors looking to invest in the company. While revenue growth has increased by 9.598% to $86.27 million, the overall financial picture is not as positive as this growth might indicate.
|
| Per Share |
Current |
| Earnings (TTM) |
-0.09 $ |
| Revenues (TTM) |
1.76 $
|
| Cash Flow (TTM) |
- |
| Cash |
0.81 $
|
| Book Value |
0.63 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-0.09 $
|
| Revenues (TTM) |
1.76 $ |
| Cash Flow (TTM) |
- |
| Cash |
0.81 $
|
| Book Value |
0.63 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
| Galafold |
|
 83.7 % |
of total Revenue |
| Pombiliti Opfolda |
|
16.86 % |
of total Revenue |
| UNITED STATES Galafold |
|
32.25 % |
of total Revenue |
| UNITED STATES Pombiliti Opfolda |
|
7.89 % |
of total Revenue |
| Non-US Galafold |
|
51.45 % |
of total Revenue |
| Non-US Pombiliti Opfolda |
|
8.97 % |
of total Revenue |
| |
On January 12 2025 the Amicus Therapeutics Inc provided following guidance
nnAmicus Therapeutics Inc. Provides Preliminary 2024 Revenue Figures and Strategic Outlook for 2025nn
Amicus Therapeutics Inc. has announced its preliminary revenue figures for 2024, revealing a total revenue of $528 million. This impressive figure signifies a robust growth rate of 32% compared to the previous year, highlighting the company?s strong performance and successful market strategies.
As we look ahead to 2025, the company has outlined its strategic goals and objectives, emphasizing a commitment to sustaining this growth trajectory. The financial guidance offered by Amicus underscores their confidence in continued expansion and the potential for increased market presence.
|
|
|
1.88%